{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:16:12Z","timestamp":1765545372639},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cathepsin K is a cysteine protease that plays an essential role in osteoclast-mediated degradation of the organic matrix of bone. Knockout of the enzyme in mice, as well as lack of functional enzyme in the human condition pycnodysostosis, results in osteopetrosis. These results suggests that inhibition of the human enzyme may provide protection from bone loss in states of elevated bone turnover, such as postmenopausal osteoporosis. To test this theory, we have produced a small molecule inhibitor of human cathepsin K, SB-357114, that potently and selectively inhibits this enzyme (Ki = 0.16 nM). This compound potently inhibited cathepsin activity in situ, in human osteoclasts (inhibitor concentration [IC]50 = 70 nM) as well as bone resorption mediated by human osteoclasts in vitro (IC50 = 29 nM). Using SB-357114, we evaluated the effect of inhibition of cathepsin K on bone resorption in vivo using a nonhuman primate model of postmenopausal bone loss in which the active form of cathepsin K is identical to the human orthologue. A gonadotropin-releasing hormone agonist (GnRHa) was used to render cynomolgus monkeys estrogen deficient, which led to an increase in bone turnover. Treatment with SB-357114 (12 mg\/kg subcutaneously) resulted in a significant reduction in serum markers of bone resorption relative to untreated controls. The effect was observed 1.5 h after the first dose and was maintained for 24 h. After 5 days of dosing, the reductions in N-terminal telopeptides (NTx) and C-terminal telopeptides (CTx) of type I collagen were 61% and 67%, respectively. A decrease in serum osteocalcin of 22% was also observed. These data show that inhibition of cathepsin K results in a significant reduction of bone resorption in vivo and provide further evidence that this may be a viable approach to the treatment of postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1359\/jbmr.2001.16.10.1739","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T03:14:25Z","timestamp":1146107665000},"page":"1739-1746","source":"Crossref","is-referenced-by-count":131,"title":["Potent and Selective Inhibition of Human Cathepsin K Leads to Inhibition of Bone Resorption In Vivo in a Nonhuman Primate"],"prefix":"10.1093","volume":"16","author":[{"given":"George B.","family":"Stroup","sequence":"first","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Lark","sequence":"additional","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Veber","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Department of Statistical Sciences, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Blake","sequence":"additional","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Dare","sequence":"additional","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl F.","family":"Erhard","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra J.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian E.","family":"James","sequence":"additional","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Marquis","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ru","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice A.","family":"Vasko-Moser","sequence":"additional","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thadeus","family":"Tomaszek","sequence":"additional","affiliation":[{"name":"Department of Mechanistic Enzymology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine","family":"Gowen","sequence":"additional","affiliation":[{"name":"Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020714120871700_bib1","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","article-title":"Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts","volume":"271","author":"Drake","year":"1996","journal-title":"J Biol Chem"},{"key":"2024020714120871700_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/bmme.1996.0088","article-title":"Cathepsin K: Isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene","volume":"59","author":"Gelb","year":"1996","journal-title":"Biochem Mol Med"},{"key":"2024020714120871700_bib3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"key":"2024020714120871700_bib4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1101\/gr.6.11.1050","article-title":"A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis","volume":"6","author":"Johnson","year":"1996","journal-title":"Genome Research"},{"key":"2024020714120871700_bib5","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","article-title":"Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization","volume":"14","author":"Gowen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib6","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024020714120871700_bib7","doi-asserted-by":"crossref","first-page":"15893","DOI":"10.1021\/bi991193+","article-title":"Mechanism of inhibition of cathepsin K by potent, selective 1,5-diacylcarbohydrazides: A new class of mechanism-based inhibitors of thiol proteases","volume":"38","author":"Bossard","year":"1999","journal-title":"Biochemistry"},{"key":"2024020714120871700_bib8","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1359\/jbmr.1997.12.9.1396","article-title":"Peptide aldehyde inhibitors of cathepsin k inhibit bone resorption both in vitro and in vivo","volume":"12","author":"Votta","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0968-0896(99)00011-5","article-title":"Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K","volume":"7","author":"Marquis","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"2024020714120871700_bib10","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1021\/jm980295f","article-title":"Conformationally constrained 1,3-diamino ketones\u2014a series of potent inhibitors of the cysteine protease cathepsin K","volume":"41","author":"Marquis","year":"1998","journal-title":"J Med Chem"},{"key":"2024020714120871700_bib11","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1074\/jbc.272.13.8109","article-title":"Cathepsin k antisense oligodeoxynucleotide inhibits osteoclastic bone resorption","volume":"272","author":"Inui","year":"1997","journal-title":"J Biol Chem"},{"key":"2024020714120871700_bib12","first-page":"453","author":"Veber","year":"2000"},{"key":"2024020714120871700_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/prep.1998.0965","article-title":"Cynomolgus monkey (Macaca fascicularis) cathepsin K: Cloning, expression, purification, and activation","volume":"14","author":"McQueney","year":"1998","journal-title":"Protein Express Purification"},{"key":"2024020714120871700_bib14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S8756-3282(01)00421-5","article-title":"Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: A short-term model for evaluation of antiresorptive therapy","volume":"28","author":"Stroup","year":"2001","journal-title":"Bone"},{"key":"2024020714120871700_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/jm000320t","article-title":"Cyclic ketone inhibitors of the cysteine protease cathepsin K","volume":"44","author":"Marquis","year":"2001","journal-title":"J Med Chem"},{"key":"2024020714120871700_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0076-6879(79)63008-2","article-title":"Statistical analysis of enzyme kinetic data","volume":"63","author":"Cleland","year":"1979","journal-title":"Methods Enzymol"},{"key":"2024020714120871700_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1359\/jbmr.2001.16.3.478","article-title":"Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption","volume":"16","author":"Dodds","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/jbmr.5650111012","article-title":"Human osteoclastoma-derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo","volume":"11","author":"James","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib19","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1359\/jbmr.1999.14.9.1562","article-title":"Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents","volume":"14","author":"James","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/jbmr.5650110212","article-title":"Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay","volume":"11","author":"Foged","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s002239900497","article-title":"Application of a new serum assay for type i collagen cross-linked n-telopeptides\u2014assessment of diurnal changes in bone turnover with and without alendronate treatment","volume":"63","author":"Gertz","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"2024020714120871700_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S8756-3282(99)00270-7","article-title":"Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope","volume":"26","author":"Atley","year":"2000","journal-title":"Bone"},{"key":"2024020714120871700_bib23","doi-asserted-by":"crossref","first-page":"32347","DOI":"10.1074\/jbc.273.48.32347","article-title":"The collagenolytic activity of cathepsin K is unique among mammalian proteinases","volume":"273","author":"Garnero","year":"1998","journal-title":"J Biol Chem"},{"key":"2024020714120871700_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/bj3310727","article-title":"Human cathepsin K cleaves native type i and ii collagens at the n-terminal end of the triple helix","volume":"331","author":"Kafienah","year":"1998","journal-title":"Biochem J"},{"key":"2024020714120871700_bib25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1359\/jbmr.1998.13.9.1420","article-title":"Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone","volume":"13","author":"Everts","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib26","doi-asserted-by":"crossref","first-page":"11507","DOI":"10.1074\/jbc.M010684200","article-title":"Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro","volume":"276","author":"James","year":"2001","journal-title":"J Biol Chem"},{"key":"2024020714120871700_bib27","first-page":"3076","article-title":"Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial","volume":"84","author":"Lindsay","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714120871700_bib28","first-page":"1904","article-title":"The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation","volume":"82","author":"Rosen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714120871700_bib29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"2024020714120871700_bib30","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women\u2014a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020714120871700_bib31","first-page":"227","article-title":"Treatment of osteoporoses by manipulation of coherent bone cell populations","volume":"143","author":"Frost","year":"1979","journal-title":"Clin Orthop Relat Res"},{"key":"2024020714120871700_bib32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/jcem-66-4-747","article-title":"Coherence therapy does not prevent axial bone loss in osteoporotic women: A preliminary comparative study","volume":"66","author":"Pacifici","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714120871700_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/8756-3282(91)90038-K","article-title":"The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime","volume":"12","author":"Steiniche","year":"1991","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2001.16.10.1739","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/16\/10\/1739\/56605282\/5650161001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/16\/10\/1739\/56605282\/5650161001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:01:31Z","timestamp":1710342091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/16\/10\/1739-1746\/7515848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2001.16.10.1739","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,10,1]]},"published":{"date-parts":[[2001,10,1]]}}}